VYNE Therapeutics (VYNE) Inventory Average (2020 - 2021)
VYNE Therapeutics (VYNE) posted Inventory Average of $7.7 million for Q4 2021, down 6.04% on a QoQ basis from $8.2 million in Q3 2021, and up 9.3% year-over-year from $7.0 million in Q4 2020.
VYNE Therapeutics (VYNE) Inventory Average (2020 - 2021) Analysis & Trends
VYNE Therapeutics' Inventory Average history runs 2 years deep, the most recent figure standing at $7.7 million for Q4 2021.
- Quarterly Inventory Average rose 9.3% year-over-year to $7.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $7.7 million (up 9.3% YoY) and the FY2021 annual result came in at $7.3 million, up 67.75% from the prior year.
- Inventory Average was $7.7 million for Q4 2021 at VYNE Therapeutics, down from $8.2 million in the prior quarter.
- Across five years, Inventory Average topped out at $8.2 million in Q2 2021 and bottomed at $2.3 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 644.91 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.73 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.15 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 7.68 Mn |
| Sep 30, 2021 | 8.17 Mn |
| Jun 30, 2021 | 8.19 Mn |
| Mar 31, 2021 | 7.75 Mn |
| Dec 31, 2020 | 7.03 Mn |
| Sep 30, 2020 | 6.23 Mn |
| Jun 30, 2020 | 4.50 Mn |
| Mar 31, 2020 | 2.28 Mn |